New drug cocktail targets tough lung cancer

NCT ID NCT06179069

Recruiting now Disease control Sponsor: Zai Lab (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study tests a new drug called ZL-1310, alone or with standard treatments (atezolizumab and carboplatin), in people with small cell lung cancer. About 339 participants will join to see if the combination is safe and shrinks tumors. The goal is to find better ways to control this aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZL-1310 (a drug) combined with atezolizumab and carboplatin
What this could lead to: If successful, this could point toward a new treatment option for small cell lung cancer, potentially improving tumor control and survival.
What could go wrong: This is an early Phase 1 trial, so safety and effectiveness are not yet proven. Side effects may occur, and the drug may not work for all participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLC

Contacts and locations

Locations

Zai Lab 1002
RECRUITING

Wuhan, Hubei, 430022, China
Zai Lab Site 1001
RECRUITING

Guangzhou, Guangdong, 510030, China
Zai Lab Site 1003
RECRUITING

Nanchang, Jiangxi, 330006, China
Zai Lab Site 1004
RECRUITING

Hefei, Anhui, 230022, China
Zai Lab Site 1005
RECRUITING

Beijing, Beijing Municipality, 100142, China
Zai Lab Site 1006
RECRUITING

Zhengzhou, Henan, 450008, China
Zai Lab Site 1008
RECRUITING

Ch’ang-ch’un, Jilin, 130012, China
Zai Lab Site 1009
NOT_YET_RECRUITING

Harbin, Heilongjiang, 150000, China
Zai Lab Site 1010
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Zai Lab Site 1011
RECRUITING

Jinan, Shandong, 250000, China
Zai Lab Site 1012
NOT_YET_RECRUITING

Xiamen, Fujian, 361000, China
Zai Lab Site 1013
RECRUITING

Chengdu, Sichaun, 610041, China
Zai Lab Site 1014
NOT_YET_RECRUITING

Changsha, Hunan, 410013, China
Zai Lab Site 1015
NOT_YET_RECRUITING

Xi'an, Shaanxi, 710061, China
Zai Lab Site 1016
RECRUITING

Nanjing, Jiangsu, 210008, China
Zai Lab Site 1017
NOT_YET_RECRUITING

Shenyang, Liaoning, 110041, China
Zai Lab Site 2001
RECRUITING

Hackensack, New Jersey, 07601, United States
Zai Lab Site 2002
RECRUITING

Buffalo, New York, 14263, United States
Zai Lab Site 2005
RECRUITING

Duarte, California, 91010, United States
Zai Lab Site 2006
RECRUITING

Fairfax, Virginia, 22031, United States
Zai Lab Site 2012
RECRUITING

Charleston, South Carolina, 29425, United States
Zai Lab Site 2013
RECRUITING

Detroit, Michigan, 48201, United States
Zai Lab Site 2018
RECRUITING

Durham, North Carolina, 27710, United States
Zai Lab Site 2024
RECRUITING

Cleveland, Ohio, 44106, United States
Zai Lab Site 2026
RECRUITING

Sarasota, Florida, 34232, United States
Zai Lab Site 2029
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Zai Lab Site 2030
RECRUITING

New Haven, Connecticut, 06519, United States
Zai Lab Site 8001
RECRUITING

Valencia, Valencia, 46026, Spain
Zai Lab Site 8002
RECRUITING

Barcelona, Barcelona, 8035, Spain
Zai Lab Site 8003
RECRUITING

Madrid, Madrid, 28034, Spain
Zai Lab Site 8004
RECRUITING

Valencia, Valencia, 46010, Spain
Zai Lab Site 8005
RECRUITING

Seville, Sevilla, 41009, Spain
Zai Lab Site 8006
RECRUITING

Madrid, Madrid, 28041, Spain
Zai Lab Site 8007
NOT_YET_RECRUITING

Barcelona, 08023, Spain
Zai Lab Site 8008
NOT_YET_RECRUITING

Málaga, 29010, Spain
Zai Lab Site 8009
NOT_YET_RECRUITING

Madrid, 28050, Spain
Zai Lab Site 8010
NOT_YET_RECRUITING

Pozuelo de Alarcón, 28223, Spain
Zai Lab Site 8011
NOT_YET_RECRUITING

Seville, 41013, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.